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patients (67.6%) in the oxybutynin IR group. Of those
with a stopping therapy record, discontinuation rates due
to poor tolerability were 3.4% versus 14.4% (p < 0.01)
for the XL and IR groups, respectively. The most frequent
recorded reason for the oxybutynin IR group was change
in formulation or titration, 20.8% compared to 4.8% for
the XL group, followed by poor tolerability, and lack of
effect (8.3% for the IR group compared to 3.4% for the
XL group). Of the 216 oxybutynin IR patients, 120 sub-
sequently switched to oxybutynin XL. CONCLUSIONS:
The improved tolerability of oxybutynin XL compared to
oxybutynin IR demonstrated in randomized clinical trials
is reﬂected in the UK real-world clinical practice setting:
patients on oxybutynin XL have signiﬁcantly lower dis-
continuation rates.
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OBJECTIVES: To assess long-term persistence with 
statin use in the general population and to identify 
determinants of failure to persist with these drugs.
METHODS: Data were obtained from the PHARMO
database including linked pharmacy records and hospital
discharge records of 865,000 subjects in The Nether-
lands. In the period 1998–2001, all new users of statins,
deﬁned as patients not receiving any statin for at least 
2 years before the ﬁrst dispensing of a statin, were
extracted. Episodes of statin use were constructed for
each patient. In case of interruptions between two pre-
scriptions of <45 days, the episode was considered 
uninterrupted. The effects of several determinants on per-
sistence in the ﬁrst episode were assessed using Cox pro-
portional hazard analysis RESULTS: A total of 8335
starters with statins were selected. Persistence with use at
one year was 63.7% (95% CI 62.7%–64.8%) for all
statins, and decreased to 48.5% (95% CI 47.4%–49.6%)
at two years. Determinants predicting failure to persist
included older age (RR = 0.82; 95% CI 0.74–0.91 for
those >65 years compared to those <45 years), a history
of antihypertensive drug use (RR = 0.91; 95% CI
0.85–0.98), psychotropic drug use (RR = 1.13; 95% CI
1.06–1.20), or hospitalisation for ischaemic heart disease
(RR = 0.78; 95% CI 0.70–0.88). Compared to starters
with simvastatin, the risk of discontinuation was lower
for atorvastatin (RR = 0.90; 95% CI 0.83–0.96), similar
for pravastatin (RR = 0.99; 95% CI 0.91–1.08), and
higher for ﬂuvastatin (RR = 1.27; 95% CI 1.12–1.39).
CONCLUSIONS: Persistence with statin use declined
over time, and is low compared to trial settings. Hence,
the number of patients needed to treat to prevent one
coronary event as observed in these trials drastically
increases in daily medical practice.
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OBJECTIVES: The purpose of this pharmacoeconomic
analysis was to compare the cost effectiveness of r-hCG
(Ovidrel®) and u-hCG (Novarel®) for ART in the USA.
Customized mathematical modeling of the economics of
infertility treatment was used to overcome the limitations
of clinical studies. METHODS: The mathematical model
incorporated a Markov varying decision framework and
Monte-Carlo computerized multiple simulations. Statisti-
cal representations of recurrent events over time were
incorporated into a decision analysis involving fresh and
frozen cycles in any sequence (after the ﬁrst fresh embryo
transfer cycle) over three successive ART attempts. Dif-
ferential information used in the model came from a 
speciﬁc meta-analysis of three published clinical trials.
Outcomes were expressed in terms of percentage of live
births and percentage of singletons. Transition probabil-
ities were derived from the medical literature and statis-
tical reports. Information concerning ART and antenatal
costs came from statistical surveys. The speciﬁc distribu-
tion curve of antenatal costs in the USA was incorporated
into the model according to a gamma distribution. The
distribution of transition probabilities was analyzed
according to a normal distribution. Costs and cost-
effectiveness were calculated from both the societal 
perspective and the managed care organization (MCO)
perspective. RESULTS: This study involved 5,000 Monte-
Carlo treatment simulations on a Markov cohort of
100,000 patients. The live birth rate and the rate of sin-
gleton births were signiﬁcantly higher with r-hCG com-
pared with u-hCG (25.97% vs. 23.58% for live births 
p < 0.001 and 21.25% vs. 16% for singleton births p <
0.001). From the societal perspective, the cost per live
birth (US $72,671 vs. US $87,376) and per singleton birth
(US $89,005 vs. US $130,007) was signiﬁcantly lower
with r-hCG compared with u-hCG (p < 0.001 for both
cases). Costs were also signiﬁcantly lower with r-hCG
from the MCO perspective: US $49,444 vs. US $59,741
per live birth (p < 0.001) and US $60,562 vs. US $88,894
per singleton birth (p < 0.001). CONCLUSION: r-hCG
is more cost-effective than u-hCG.
